Catalyst Pharmaceutical Inc (NASDAQ: CPRX) has benefited from meaningful positive changes in fundamentals: the consensus estimate for December, 2024 increased significantly, the stock’s power rating rose above 70, and the consensus estimate for December, 2025 increased significantly.
Recent notable positive changes in investment behavior have benefitted Catalyst Pharmaceutical Inc (NASDAQ: CPRX): positive upside/downside volume developed.
In light of these very positive signals we are reviewing our current Overall Rating of A. We would continue to view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, CPRX is expected to continue to be a major Value Builder.
Catalyst Pharmaceutical has a current Value Trend Rating of A (Highest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Catalyst Pharmaceutical has a good Power Rating of 71 and a very high Appreciation Score of 91, triggering the Highest Value Trend Rating.
Recent Price Action
Catalyst Pharmaceutical Inc (NASDAQ: CPRX) stock closed at $19.91 on 9/4/24 after a modest gain of 0.9%. NORMAL trading volume accompanied the advance. The stock has declined -3.1% during the last week but has been strong relative to the market over the last nine months.
Be the first to comment